论文部分内容阅读
Aim: To observe the serum androgen changes in patients with prostate cancer (PCa) before and after castration. Methods: Serum testosterone (T), free testosterone (FT) and dihydrotest-osterone (DHT) were determined with radioimmunoassay in 16 cases with PCa one week before and on day 5 after castration. Results: After castration, the serum T, FT and DHT levels significantly declined by 92.27 %, 92.26 % and 58.36 %, respectively, as compared with the pre-castration values (P<0.01). Conclusion: After castration, most T and FT were deprived, while DHT only declined 58.36 %. Androgen receptor competitor should still be administered to antagnize the action of the remaining androgens.
Aim: To observe the serum androgen changes in patients with prostate cancer (PCa) before and after castration. Methods: Serum testosterone (T), free testosterone (FT) and dihydrotest-osterone (DHT) were determined with radioimmunoassay in 16 cases with PCa one week before and on day 5 after castration. Results: After castration, the serum T, FT and DHT levels were significantly decreased by 92.27%, 92.26% and 58.36%, respectively, as compared with the pre-castration values (P <0.01) Conclusion: After castration, most T and FT were deprived, while DHT only declined 58.36%. Androgen receptor competitor should still be administered to antagnize the action of the remaining and roots.